Deutsche Bank Analysts Give Sartorius (FRA:SRT3) a €200.00 Price Target

Share on StockTwits

Sartorius (FRA:SRT3) has been assigned a €200.00 ($232.56) price target by research analysts at Deutsche Bank in a research report issued on Tuesday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. Deutsche Bank’s price target would suggest a potential downside of 6.28% from the company’s current price.

Other equities analysts have also issued reports about the stock. Berenberg Bank set a €145.00 ($168.60) price objective on shares of Sartorius and gave the company a “sell” rating in a research report on Monday, October 21st. Nord/LB set a €150.00 ($174.42) price objective on shares of Sartorius and gave the company a “sell” rating in a research report on Friday, October 25th. Warburg Research set a €184.00 ($213.95) price objective on shares of Sartorius and gave the company a “neutral” rating in a research report on Monday, October 21st. UBS Group set a €192.00 ($223.26) target price on shares of Sartorius and gave the company a “neutral” rating in a research note on Monday, December 9th. Finally, JPMorgan Chase & Co. set a €205.00 ($238.37) target price on shares of Sartorius and gave the company a “buy” rating in a research note on Monday, January 6th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of €166.56 ($193.67).

SRT3 stock opened at €213.40 ($248.14) on Tuesday. The firm has a 50 day moving average of €195.31 and a 200-day moving average of €181.85. Sartorius has a 12 month low of €71.00 ($82.56) and a 12 month high of €124.70 ($145.00).

About Sartorius

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Recommended Story: Understanding Market Liquidity

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hasbro, Inc.  Expected to Earn Q1 2020 Earnings of $0.01 Per Share
Hasbro, Inc. Expected to Earn Q1 2020 Earnings of $0.01 Per Share
Halozyme Therapeutics, Inc.  to Post Q1 2020 Earnings of  Per Share, Piper Sandler Forecasts
Halozyme Therapeutics, Inc. to Post Q1 2020 Earnings of Per Share, Piper Sandler Forecasts
Q1 2020 EPS Estimates for Helios Technologies  Boosted by William Blair
Q1 2020 EPS Estimates for Helios Technologies Boosted by William Blair
Aergo Price Down 15.4% This Week
Aergo Price Down 15.4% This Week
Skychain  Market Capitalization Achieves $662,118.00
Skychain Market Capitalization Achieves $662,118.00
EveriToken  Trading Down 27.4% Over Last Week
EveriToken Trading Down 27.4% Over Last Week


 
© 2006-2020 Zolmax.